Urogen Pharma (URGN)
(Delayed Data from NSDQ)
$15.30 USD
-0.38 (-2.42%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $15.32 +0.02 (0.13%) 4:28 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Urogen Pharma falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -102.24 | -109.78 | -110.82 | -128.48 | -105.15 |
Depreciation/Amortization & Depletion | -0.23 | 0.43 | 1.31 | 0.86 | -0.28 |
Net Change from Assets/Liabilities | 3.34 | -6.31 | -13.11 | -7.91 | 3.41 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 22.76 | 28.10 | 37.73 | 29.65 | 31.00 |
Net Cash From Operating Activities | -76.38 | -87.56 | -84.89 | -105.89 | -71.02 |
Property & Equipment | -0.19 | -0.25 | -0.75 | -1.22 | -0.33 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -0.76 | 1.31 | 4.82 | 94.45 | -145.10 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | -0.17 |
Net Cash from Investing Activities | -0.95 | 1.06 | 4.07 | 93.24 | -145.59 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 116.93 | 1.51 | 0.06 | 16.59 | 165.33 |
Issuance (Repayment) of Debt | 0.00 | 95.78 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | -0.16 | 72.26 | -0.07 | -0.08 |
Net Cash from Financing Activities | 116.93 | 97.13 | 72.32 | 16.53 | 165.25 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 39.60 | 10.64 | -8.50 | 3.88 | -51.36 |
Cash at Beginning of Period | 56.22 | 45.59 | 54.09 | 50.21 | 101.57 |
Cash at End of Period | 95.82 | 56.22 | 45.59 | 54.09 | 50.21 |
Diluted Net EPS | -3.55 | -4.81 | -4.96 | -5.90 | -5.12 |
Fiscal Year End for Urogen Pharma falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -32.29 | -102.24 | -76.23 | -54.35 |
Depreciation/Amortization & Depletion | NA | -0.06 | -0.23 | -0.01 | -0.24 |
Net Change from Assets/Liabilities | NA | -4.01 | 3.34 | -4.24 | -3.18 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 4.62 | 22.76 | 17.10 | 11.69 |
Net Cash From Operating Activities | NA | -31.74 | -76.38 | -63.38 | -46.08 |
Property & Equipment | NA | 0.00 | -0.19 | -0.14 | -0.04 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 13.52 | -0.76 | 10.53 | 10.03 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 13.52 | -0.95 | 10.39 | 9.99 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 54.66 | 116.93 | 116.89 | 0.81 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 54.66 | 116.93 | 116.89 | 0.81 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 36.44 | 39.60 | 63.90 | -35.28 |
Cash at Beginning of Period | NA | 95.82 | 56.22 | 56.22 | 56.22 |
Cash at End of Period | NA | 132.26 | 95.82 | 120.12 | 20.94 |
Diluted Net EPS | NA | -0.97 | -0.54 | -0.68 | -1.03 |